NASDAQ:ABEO

Abeona Therapeutics Stock Forecast, Price & News

$1.54
+0.02 (+1.32 %)
(As of 05/7/2021 05:20 PM ET)
Add
Compare
Today's Range
$1.50
$1.60
50-Day Range
$1.41
$2.31
52-Week Range
$0.99
$3.79
Volume775,320 shs
Average Volume3.48 million shs
Market Capitalization$152.52 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69
30 days | 90 days | 365 days | Advanced Chart
Receive ABEO News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ABEO
Previous SymbolOTCMKTS:ACCP
CUSIPN/A
Phone214-665-9495
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$3 million
Book Value$2.13 per share

Profitability

Net Income$-76,280,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap$152.52 million
Next Earnings DateN/A
OptionableOptionable

Headlines

See More Headlines
Abeona Therapeutics logo

About Abeona Therapeutics

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

MarketRank

Overall MarketRank

1.58 out of 5 stars

Medical Sector

432nd out of 2,041 stocks

Pharmaceutical Preparations Industry

203rd out of 769 stocks

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Abeona Therapeutics (NASDAQ:ABEO) Frequently Asked Questions

Is Abeona Therapeutics a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Abeona Therapeutics stock.
View analyst ratings for Abeona Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Abeona Therapeutics?

Wall Street analysts have given Abeona Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abeona Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Abeona Therapeutics?

Abeona Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 6,110,000 shares, an increase of 25.2% from the March 31st total of 4,880,000 shares. Based on an average daily volume of 3,810,000 shares, the short-interest ratio is presently 1.6 days.
View Abeona Therapeutics' Short Interest
.

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) posted its quarterly earnings data on Tuesday, March, 23rd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.07. The biopharmaceutical company earned $3 million during the quarter, compared to the consensus estimate of $5.55 million.
View Abeona Therapeutics' earnings history
.

How has Abeona Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Abeona Therapeutics' stock was trading at $2.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABEO shares have decreased by 30.1% and is now trading at $1.53.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ABEO?

6 equities research analysts have issued 12-month price targets for Abeona Therapeutics' stock. Their forecasts range from $3.00 to $8.00. On average, they expect Abeona Therapeutics' stock price to reach $5.17 in the next year. This suggests a possible upside of 237.7% from the stock's current price.
View analysts' price targets for Abeona Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the following people:
  • Mr. Steven H. Rouhandeh, Exec. Chairman (Age 61)
  • Dr. Timothy J. Miller, Pres, Chief Scientific Officer & Director (Age 46)
  • Mr. Jeffrey Blaine Davis, Chief Operating Officer (Age 55)
  • Mr. Carsten Thiel, Chief Exec. Officer (Age 54)
  • Mr. Stephen B. Thompson, Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer (Age 64)

Who are some of Abeona Therapeutics' key competitors?

What other stocks do shareholders of Abeona Therapeutics own?

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.47%), Assenagon Asset Management S.A. (0.15%), Migdal Insurance & Financial Holdings Ltd. (0.09%), BNP Paribas Arbitrage SA (0.02%) and WealthTrust Axiom LLC (0.02%). Company insiders that own Abeona Therapeutics stock include Edward Carr, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc, Stefano Buono and Todd Wider.
View institutional ownership trends for Abeona Therapeutics
.

Which major investors are buying Abeona Therapeutics stock?

ABEO stock was purchased by a variety of institutional investors in the last quarter, including Los Angeles Capital Management LLC, Migdal Insurance & Financial Holdings Ltd., Assenagon Asset Management S.A., WealthTrust Axiom LLC, and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Abeona Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abeona Therapeutics' stock price today?

One share of ABEO stock can currently be purchased for approximately $1.53.

How much money does Abeona Therapeutics make?

Abeona Therapeutics has a market capitalization of $151.53 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-76,280,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

What is Abeona Therapeutics' official website?

The official website for Abeona Therapeutics is www.abeonatherapeutics.com.

Where are Abeona Therapeutics' headquarters?

Abeona Therapeutics is headquartered at 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The biopharmaceutical company can be reached via phone at 214-665-9495 or via email at [email protected]


This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.